ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS / OncoDaily

oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology


Saturday, March 7, 2026, 9:22 am / permalink 20321 / 3 stories in 3 days



Related Stories




Related Tags



StackHealth Time Machine





NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.